ADR,SEQ,PT,HLT,HLGT,SOC_ABBREV,FATAL_YN
1,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
1,2,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
1,3,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
1,4,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
1,5,Feeling hot,Feelings and sensations NEC,General system disorders NEC,Genrl,N
1,6,Flushing,Peripheral vascular disorders NEC,Vascular disorders NEC,Vasc,N
2,1,Coagulation factor VIII level decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2,2,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
2,3,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
2,4,Inhibiting antibodies,Immunology analyses NEC,Immunology and allergy investigations,Inv,N
3,1,Coagulation factor decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
5,1,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
6,1,Drug level decreased,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
7,1,Coagulation factor VIII level decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
8,1,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
8,2,Flushing,Peripheral vascular disorders NEC,Vascular disorders NEC,Vasc,N
9,1,Coagulation factor VIII level decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
9,2,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
10,1,Anti-polyethylene glycol antibody present,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
10,2,Coagulation factor VIII level decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
10,3,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
10,4,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
11,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
12,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
13,1,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
13,2,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
13,3,Flushing,Peripheral vascular disorders NEC,Vascular disorders NEC,Vasc,N
13,4,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
13,5,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
14,1,Device issue,Device issues NEC,Device issues,Prod,N
14,2,Product preparation issue,Product preparation errors and issues,Medication errors and other product use errors and issues,Inj&P,N
15,1,Anti-polyethylene glycol antibody present,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
15,2,Drug trough level,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
16,1,Coagulation factor VIII level decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
17,1,Haemarthrosis,Arthropathies NEC,Joint disorders,Musc,N
18,1,Anti-polyethylene glycol antibody present,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
18,2,Drug half-life reduced,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
18,3,Muscle haemorrhage,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
19,1,Product prescribing error,Product prescribing errors and issues,Medication errors and other product use errors and issues,Inj&P,N
20,1,Coagulation factor VIII level decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
21,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
22,1,Anti-polyethylene glycol antibody present,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
22,2,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
23,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
23,2,Flushing,Peripheral vascular disorders NEC,Vascular disorders NEC,Vasc,N
24,1,Drug effect less than expected,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
24,2,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
25,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
25,2,Flushing,Peripheral vascular disorders NEC,Vascular disorders NEC,Vasc,N
26,1,Haemophilia A with anti factor VIII,Coagulation disorders congenital,Blood and lymphatic system disorders congenital,Cong,N
